Obulytix strengthens its role in BEAM Alliance with Board representation

Obulytix recently joined the BEAM Alliance, a leading European network of small and medium-sized enterprises (SMEs) committed to combating antimicrobial resistance (AMR). Becoming part of this strategic coalition strengthens Obulytix’s engagement in the broader European AMR innovation ecosystem.

About the BEAM Alliance

The BEAM Alliance brings together biotechnology companies developing innovative solutions against drug‑resistant infections. The network actively collaborates with European policymakers, funding bodies, and global health stakeholders to improve the innovation landscape for antimicrobial research and development.

Obulytix CEO appointed to the BEAM Alliance Board of Directors

As part of this engagement, Kristof Van Emelen, CEO of Obulytix, was recently elected to the Board of Directors of BEAM Alliance. His appointment further strengthens Obulytix’s involvement in the alliance’s strategic discussions on advancing antimicrobial innovation in Europe.

Supporting structural innovation in AMR

Antimicrobial resistance remains one of the most pressing public health threats worldwide. While scientific innovation continues to generate promising new technologies, structural challenges in funding, regulatory pathways and market access often limit the translation of these innovations into approved therapies. Through its involvement in the BEAM Alliance, Obulytix contributes to efforts aimed at overcoming these challenges.

Our key contributions include:

• Advocating for sustainable innovation models in antimicrobial development

• Engaging in policy dialogue to reinforce Europe’s AMR ecosystem

• Collaborating internationally with biotech companies developing next‑generation antibacterial solutions

For more information about BEAM Alliance, visit: https://beam-alliance.eu/